Mizuho Securities analyst Difei Yang reiterated a Hold rating on Bluebird Bio (BLUE – Research Report) today and set a
Tag: Difei Yang
Mizuho Securities Thinks Avrobio’s Stock is Going to Recover
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Avrobio (AVRO – Research Report),
Mizuho Securities Thinks Avrobio’s Stock is Going to Recover
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Avrobio (AVRO – Research Report),
Mizuho Securities Maintains a Buy Rating on Xeris Pharmaceuticals (XERS)
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research
Analysts Offer Insights on Healthcare Companies: Selecta Biosciences (NASDAQ: SELB) and Regulus (NASDAQ: RGLS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Selecta Biosciences (SELB
Mizuho Securities Thinks Avrobio’s Stock is Going to Recover
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Avrobio (AVRO – Research Report),
Why Did Mizuho Securities Downgrade Bluebird Bio’s Stock?
Bluebird Bio (BLUE – Research Report) received a Hold rating and a $34.00 price target from Mizuho Securities analyst Difei